Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN11974092
ISRCTN11974092
Completed
Not Applicable

A phase I/II study of vaccination against minor histocompatibility antigens HA1 or HA2 after allogeneic stem cell transplantation for advanced haematological malignancies

Hannover Medical School (Medizinischen Hochschule Hannover) (Germany)0 sites25 target enrollmentNovember 20, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Hannover Medical School (Medizinischen Hochschule Hannover) (Germany)
Enrollment
25
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 20, 2008
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Hannover Medical School (Medizinischen Hochschule Hannover) (Germany)

Eligibility Criteria

Inclusion Criteria

  • •1\. Advanced (high risk) leukaemia, after allogeneic haematopoietic stem cell transplantation (HSCT)
  • •2\. Disparity in HA1 or HA2 between donor and recipient
  • •3\. Informed consent
  • •4\. Aged 18 years or older, either sex

Exclusion Criteria

  • •1\. Acute or chronic graft\-versus\-host disease (GvHD) after allo\-HSCT prior to immunisation
  • •2\. No informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials

Terminated
Phase 1
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic MalignanciesPreleukemiaMyeloproliferative DisordersLymphomaMyelomaGraft Versus Host Disease
NCT00943293University of Chicago1
Active, not recruiting
Not Applicable
An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study) - NDProstate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated levels of testosterone or after first-line anti hormonal therapyMedDRA version: 12.1Level: LLTClassification code 10001200Term: Adenocarcinoma of the prostate stage I
EUCTR2009-017798-39-ITISTITUTO NAZIONALE PER LA CURA TUMORI
Active, not recruiting
Phase 1
A Study of Safety and Clinical Activity of Cancer Immunotherapy Plus Chemotherapy in Metastatic Melanoma PatientsPatients with unresectable and progressive metastatic cutaneous melanoma, whose tumor expresses MAGE-A3.MedDRA version: 16.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2008-001918-25-BEGlaxoSmithKline Biologicals40
Active, not recruiting
Phase 1
A Study of Safety and Clinical Activity of Cancer Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients
EUCTR2008-001918-25-FRGlaxoSmithKline Biologicals48
Active, not recruiting
Not Applicable
Phase I/II trial of vaccine therapy in curative resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and surviving.Prostatic cancer patients who have received curative surgery.
EUCTR2010-018770-20-NOOslo University Hospital30